Sintilimab Combined With IBI310 and Surufatinib for the Treatment of G3-NET and NEC (NESSIE)
Sintilimab Combined With IBI310 and Surufatinib for the Treatment of G3-NET and NEC (NESSIE)
Recruiting · NCT05165407 · Registry updated 2025-03-14Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Sintilimab Combined With IBI310 and Surufatinib for the Treatment of G3-NET and NEC (NESSIE) | Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, neoplasm, neuroendocrine neoplasm, primitive neuroectodermal tumor | Recruiting | Phase 2 | 2025-03-14 | NCT05165407 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Peking University | 124 |
2 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Beijing Cancer Hospital | Beijing | China | 208 |
| Bejing cancer hospital | Beijing | China | 1 |